- Home
- JWEL vs SNOA Comparison
JWEL vs SNOA Comparison
Compare JWEL & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- SNOA
- Stock Information
- Founded
- JWEL 2012
- SNOA 1999
- Country
- JWEL China
- SNOA United States
- Employees
- JWEL N/A
- SNOA N/A
- Industry
- JWEL Other Consumer Services
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- SNOA Health Care
- Exchange
- JWEL Nasdaq
- SNOA Nasdaq
- Market Cap
- JWEL 4.1M
- SNOA 4.6M
- IPO Year
- JWEL 2021
- SNOA 2007
- Fundamental
- Price
- JWEL $1.95
- SNOA $2.56
- Analyst Decision
- JWEL
- SNOA
- Analyst Count
- JWEL 0
- SNOA 0
- Target Price
- JWEL N/A
- SNOA N/A
- AVG Volume (30 Days)
- JWEL 16.1K
- SNOA 97.7K
- Earning Date
- JWEL 11-29-2024
- SNOA 11-07-2024
- Dividend Yield
- JWEL N/A
- SNOA N/A
- EPS Growth
- JWEL N/A
- SNOA N/A
- EPS
- JWEL N/A
- SNOA N/A
- Revenue
- JWEL $160,009,293.00
- SNOA $13,547,000.00
- Revenue This Year
- JWEL N/A
- SNOA $36.00
- Revenue Next Year
- JWEL N/A
- SNOA $25.26
- P/E Ratio
- JWEL N/A
- SNOA N/A
- Revenue Growth
- JWEL N/A
- SNOA 11.81
- 52 Week Low
- JWEL $1.00
- SNOA $2.52
- 52 Week High
- JWEL $3.14
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- JWEL 54.81
- SNOA 39.95
- Support Level
- JWEL $1.81
- SNOA $2.76
- Resistance Level
- JWEL $2.15
- SNOA $2.84
- Average True Range (ATR)
- JWEL 0.18
- SNOA 0.21
- MACD
- JWEL 0.01
- SNOA -0.01
- Stochastic Oscillator
- JWEL 49.09
- SNOA 0.01
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.